IBUDILAST AND TELMISARTAN FOR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE, NON ALCOHOLIC STEATOHEPATITIS, AND ADVANCED NON ALCOHOLIC STEATOHEPATITIS

摘要

Provided herein are methods of inhibiting or treating non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), advanced NASH, non-alcoholic fatty liver disease, conditions leading to or arising from them, and/or negative effects of each of the above by administering ibudilast or a pharmaceutically acceptable salt thereof in combination with an effective amount of telmisartan or an ester thereof or a pharmaceutically acceptable salt of each thereof.